Russia may face shortages of certain pain management drugs this year

Russia maybe faced with a shortage of certain pain management drugs this year, due to t he end of supplies of active ingredients for their production from the UK, according to recent statements by the director of the Moscow Endocrine Plant, Mikhail Fonarev, reports The Pharma Letter’s local correspondent.

According to the expert, currently Russian production is completely dependent on opium active ingredients that are purchased in different countries that support sanctions regime against Russia, mostly from Spain and the UK. However, the recent decision of the UK to halt these supplies means Russia will have to start a search of alternative suppliers.

Mr Fonarev believes that such a situation may negatively impact Russia’s state security in the field of pharmaceutics.